Short term effects of HMG-CoA reductase inhibition (atorvastatin) on renal hemodynamics, tubular function and vasoactive hormones on healthy subjects.

Trial Profile

Short term effects of HMG-CoA reductase inhibition (atorvastatin) on renal hemodynamics, tubular function and vasoactive hormones on healthy subjects.

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Mar 2012

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Hypercholesterolaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 16 May 2008 Status changed from in progress to completed, as reported by ClinicalTrials.gov.
    • 04 Nov 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top